4
Changes in Ownership
Oruka Therapeutics, Inc. Filed Acc 0000907654-26-000075
Senior Vice President, Finance sold 10,000 shares at an average $106.66 ($1,066,572)
- Senior Vice President, Finance acquired 10,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Agarwal Arjun · Senior Vice President, Finance
Table I: Non-derivative
7 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-08-13 | Exercise or conversion : show line 1 in the form 10b5-1 | +8,542 | $12.50 | $106,775 | 23,854 | D |
| 2026-08-13 | Exercise or conversion : show line 2 in the form 10b5-1 | +1,458 | $34.39 | $50,141 | 25,312 | D |
| 2026-08-13 | Sale : show line 3 in the form 10b5-1 | −2,100 | $104.67 | $219,814 | 23,212 | D |
| 2026-08-13 | Sale : show line 4 in the form 10b5-1 | −2,132 | $105.57 | $225,079 | 21,080 | D |
| 2026-08-13 | Sale : show line 5 in the form 10b5-1 | −1,268 | $106.63 | $135,201 | 19,812 | D |
| 2026-08-13 | Sale : show line 6 in the form 10b5-1 | −2,142 | $107.71 | $230,723 | 17,670 | D |
| 2026-08-13 | Sale : show line 7 in the form 10b5-1 | −2,358 | $108.46 | $255,755 | 15,312 | D |
| Open-market sales · 10,000 sh · avg $106.66 · $1,066,572 | ||||||
Table II: Derivative
2 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2026-08-13 | Exercise or conversion : show line 8 in the form 10b5-1 Employee Stock Option (right to buy) | −8,542 | 92,917 | D |
| 2026-08-13 | Exercise or conversion : show line 9 in the form 10b5-1 Employee Stock Option (right to buy) | −1,458 | 59,792 | D |
Loading xslF345X06/form4.xml…